Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients.

Transplant Cell Ther · 2022 · PMC9334861 · PMID 35914727

Europe PMC DOI

hedged sentence

0.0640

closest p · 1.3× alpha

0.0640

boldest claim

The sentences

did not reach statistical significanceP = .064so close (0.05 < p ≤ 0.1)

We also observed a trend toward an increase in the frequency of IFN-γ monofunctional CD4 + T-cells after the third dose, but this did not reach statistical significance (356.3 versus 401.1 CD4 + T-cells per 10 6 CD4 + T-cells, P = .064).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.